There’s a lot going on in #MusicCity tomorrow night!

RT for a chance to win these Sounds x Preds jerseys in honor of game 6.

Winner will be announced tomorrow at 3pm.

Correction: we see you Tennessee GOP. Not all of us here are utter nut jobs. 😉

Published today in Blood Journal 🎉 Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma #CART #lymsm

Great collaboration with French colleagues Roch Houot Lysa Lymphoma Pere Barba

pubmed.ncbi.nlm.nih.gov/38657242/

Marathon runners, not sprinters: the idea behind Dr. Shikhar Mehrotra's patented cytokine cocktail for #CART #immunotherapy . bit.ly/3Jxap2o

This is so sad. I’m heartbroken for the future of this state.

Smart move MNPS.

Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity ashpublications.org/blood/article/…

#Racial_disparities #CARTcell CIBMTR

NH Black patients had lower overall response rate (OR, 0.37, [95% CI, 0.22-0.63]) and lower…

I love this 😂 #letsgopreds

I’m sorry, what? You got your law degree from where?

.Vanderbilt-Ingram Cancer Center would like you to join us at our 2024 Vanderbilt Stem Cell Transplant and Cellular Therapy Symposium.

For more information on the event, or to register, please visit the link below.

spr.ly/6014wA4Ce

So proud of you!!! Danielle Murphy, APRN

Nashville represent!

Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations

chi.scholasticahq.com/article/115793

Reading this great manuscript by colleagues Katie Gatewood, our amazing superstar Zahra M, PharmD, MBA, BCOP, FHOPA, and Bhagirath Dholaria, MD! This will help our patients and decrease the financial…

Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations.
just Published in Clinical Hematology International the official journal of ⁦IACH⁩ ⁦Ola Oluwole⁩ ⁦Bipin Savani⁩ ⁦Uriel Suárez⁩ chi.scholasticahq.com/article/115793

Our Phase I TRANSCEND trial demonstrated that Liso-cel results in consistently high objective response rates and complete response rates in patients with heavily pretreated R/R #MCL , including those with high-risk disease characteristics. tinyurl.com/LISO-TRANSCEND

The best news of the week!!!!

I swear to all of the higher beings… I’m going to lose my absolute mind if this passes.

Absolutely shame on this state. More guns in schools by arming teachers is not a way to keep children safe.

So not getting facts correct and teaching children correct info is not important? Also not shocking anything from Live Action is not accurate.

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
prnewswire.com/news-releases/…